
Cogint (COGT) Stock Forecast & Price Target
Cogint (COGT) Analyst Ratings
Bulls say
Cogent Biosciences Inc. is projected to experience significant sales growth, with estimates reaching approximately $225 million by 2032 for the CGT9486 program, reflecting a robust 60% probability of success. Additionally, the company’s Bezuclastinib therapy shows a promising competitive profile compared to existing treatments, potentially capturing a meaningful market share in the advanced systemic mastocytosis space. The favorable early results from clinical trials, particularly the superior efficacy of CGT6297 in mouse models compared to existing therapies, further bolster the company's positive outlook by indicating strong potential for clinical success and market impact.
Bears say
Cogent Biosciences faces several significant risks impacting its financial outlook, including potential negative clinical data, slower-than-anticipated development timelines, and setbacks in regulatory approvals, all of which could hinder the advancement of key therapies. The company's lead candidate, bezuclastinib, may encounter challenges related to its safety profile, especially in non-advanced systemic mastocytosis, which could constrain its marketability and overall revenue potential. Additionally, the company has adjusted its projections for peak market penetration in the second-line gastrointestinal stromal tumor setting from 50% to 20%, reflecting a diminished confidence in achieving prior commercial success.
This aggregate rating is based on analysts' research of Cogint and is not a guaranteed prediction by Public.com or investment advice.
Cogint (COGT) Analyst Forecast & Price Prediction
Start investing in Cogint (COGT)
Order type
Buy in
Order amount
Est. shares
0 shares